Using a sensitive transfection-tumorigenicity assay, we have isolated a novel transforming gene from the DNA of two patients with chronic myelogenous leukemia. Sequence analysis indicates that the product of this gene, axl, is a receptor tyrosine kinase. Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein. Expression of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is recognized by antiphosphotyrosine antibodies, confirming that the axl protein is a tyrosine kinase. (12) . There are several mechanisms by which growth factor receptors can be rendered transforming. Retroviral transduction of protooncogenes can result in truncation and mutation of the normal version of the gene. This has been shown for the epidermal growth factor receptor (EGFR) (v-erbB) (18), colony-stimulating factor 1 receptor (CSF-1R) (v-fms) (68), and ros (v-ros) (52) genes. Overexpression of an otherwise normal receptor, with or without the concomitant application of ligand, can also result in neoplastic transformation, as shown for the insulinlike growth factor 1 receptor (38), EGFR (15, 77), CSF-1R (65), eph (51), and neu (16) HOS (10), has been demonstrated to be the cell surface receptor for hepatocyte growth factor, a potential growth factor for a broad spectrum of cell types as well as a mediator of liver regeneration (7). In addition, CSF-1R mediates the pleiotropic effects of its cognate ligand, CSF-1. Together, these two molecules stimulate the proliferation and differentiation of cells of the macrophage lineage (68).
Receptor tyrosine kinases represent a class of proteins that transduce signals from the extracellular milieu into the cytoplasm by binding peptide growth factors. These growth factors and their cognate receptors are involved in regulating cellular growth and differentiation. Alteration of either growth factors or their receptors can result in neoplastic transformation and altered development (12) . There are several mechanisms by which growth factor receptors can be rendered transforming. Retroviral transduction of protooncogenes can result in truncation and mutation of the normal version of the gene. This has been shown for the epidermal growth factor receptor (EGFR) (v-erbB) (18) , colony-stimulating factor 1 receptor (CSF-1R) (v-fms) (68) , and ros (v-ros) (52) genes. Overexpression of an otherwise normal receptor, with or without the concomitant application of ligand, can also result in neoplastic transformation, as shown for the insulinlike growth factor 1 receptor (38) , EGFR (15, 77) , CSF-1R (65) , eph (51) , and neu (16) genes. Furthermore, structural rearrangement, as seen with ret, trk, and met (24, 50, 59) , may also activate the transforming capacity of receptor kinases.
In addition to the transforming activity of altered or overexpressed receptor tyrosine kinases, studies have demonstrated that the normal cellular homologs of these receptors function to regulate cell growth and differentiation. Examples include the trk receptor kinase originally isolated by genomic transfection of human colon carcinoma DNA into NIH 3T3 cells (50) . Although trk is not generally involved in colon cancer, recent work has demonstrated that this gene encodes a subunit of the nerve growth factor receptor which plays a critical role in neural development (39, 40) . Furthermore, the met proto-oncogene, originally isolated by transfection of 3T3 cells with genomic DNA from the tumorigenic human osteogenic sarcoma cell line MNNG-HOS (10) , has been demonstrated to be the cell surface receptor for hepatocyte growth factor, a potential growth factor for a broad spectrum of cell types as well as a mediator of liver regeneration (7) . In addition, CSF-1R mediates the pleiotropic effects of its cognate ligand, CSF-1. Together, these two molecules stimulate the proliferation and differentiation of cells of the macrophage lineage (68) .
In an effort to determine genes involved in the progression of chronic myelogenous leukemia (CML) to acute-phase leukemia, we previously reported the identification of a transforming gene in the DNAs of two patients with CML (47) . Molecular cloning and characterization indicate that this gene, which we term axl (from the Greek word anexelekto, or uncontrolled), is a receptor tyrosine kinase with a structure novel among tyrosine kinases. Our data indicate that the ax! protein has tyrosine kinase activity and is capable of transforming NIH 3T3 cells. Furthermore, axl's transforming capacity results from overexpression of axl mRNA rather than from structural mutation.
MATERIALS AND METHODS
Identification of a transforming gene in CML cells. Transfections and nude mouse tumorigenicity assays were performed as described previously (47) . The cell lines AF6295 and AF3642 were derived from secondary nude mouse tumors arising from transfection of DNA from blast crisis and chronic-phase CML patients, respectively. Tumors were isolated from nude mice and digested in the presence of trypsin-EDTA. A portion of these cells was then plated in plastic tissue culture flasks.
Isolation of cosmid and cDNA clones. DNA fragments for cosmid cloning were generated by partial MboI digests of genomic DNA from a secondary nude mouse tumor cell line, AF6295. The restricted DNA fragments were size selected on sodium chloride gradients and cloned in the c2RB cosmid vector as previously described (4) . Following ligation, recombinants were packaged with Gigapack Gold (Stratagene, La Jolla, Calif.) according to the manufacturer's recommen-dations and used to infect Escherichia coli W46-4. The cosmid library was screened by using the Blur8 probe, which contains human Alu repetitive sequences (37) , resulting in the identification of two Alu-positive clones, 1-1 and 4-2. Unique human exon fragments were identified by differential screening of Southern blots of cosmid clones 1-1 and 4-2. Poly(A)+ RNA from both AF6295 and untransformed NIH 3T3 cells was obtained as previously described (1) . First-strand cDNA reactions were performed in a 50-,ul final volume of 0.6 mM dCTP, 1 mM each dATT, dGTT, and dTTP, 10 mM dithiothreitol, 20 Unincorporated label was separated on a Sepharose G-50 column. The resulting probes were used for Southern hybridization (1), using sheared and denatured mouse or human DNA at 100 ,ug/ml and salmon sperm DNA at 100 p,g/ml for blocking. Southern blots were also hybridized with Blur8 to identify fragments from the cosmid clones containing Alu repeat sequences. A single 2.8-kb EcoRI-BamHI fragment (pcc-1) in cosmid clone 1-1 was found to be free of Alu and mouse sequences while containing transcribed exons from the putative human transforming gene. cDNA libraries were constructed in XgtlO by using poly(A)+ RNA from AF6295. By using pcc-1 as a probe, several cDNAs were identified. Sequence analysis of these cDNAs indicated these clones were short (approximately 1 kb in size) and did not contain poly(A)+ tails. A full-length cDNA, clone 1-4, was then isolated from a size-selected, oligo(dT)-primed cDNA library constructed as described previously (26) except that 4 ,ug Chromosomal localization and fluorescence in situ chromosomal hybridization. A Southern blot of DNA from humanhamster somatic cell hybrids (BIOS, New Haven, Conn.) was probed with random-primer-labelled cDNA clones 12-1 and 1-4 and genomic clone pcc-1 under conditions recommended by the manufacturer. The filter was washed twice in 2x SSC (lx SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.5% sodium dodecyl sulfate (SDS) for 10 min at room temperature, once in 1 x SSC-1.0% SDS for 15 min at 65°C, and twice in 0.1x SSC-L.O%o SDS for 15 min at 65°C and then exposed overnight at -70°C.
For in situ hybridization, human metaphase cells were prepared from phytohemagglutinin-stimulated peripheral blood lymphocytes. The axl probe was cosmid 1-1 containing a 41-kb genomic fragment cloned in the cosmid vector c2RB. The procedure used for fluorescence in situ hybridization is a modification of the method described by Lichter et al. (45) . Biotin-labelled probes were prepared by nick translation using Bio-11-dUTP (Enzo Diagnostics, New York, N.Y.). Chromosomal DNA was denatured by immersion of the slides in 70% formamide-4 x SSC (pH 7.0) at 70°C for 2 min. Prior to hybridization, unlabelled, sonicated, total human genomic DNA (150 mg/ml) was added to the hybridization mixture (50% formamide, 1 x SSC, 10% dextran sulfate, pH 7.0) containing the labelled probe (50 to 100 ng). The hybridization mixture was heated at 75°C for 5 min and then incubated at 37°C for 5 to 10 min to promote partial reannealing. After hybridization, the slides were washed in 50% formamide-4x SSC (three washes, 5 min each) at 40°C and then in 4x SSC at 40°C (three washes, 3 min each).
Detection reagents were prepared in 4x SSC-0.1% Triton X-100-1% BSA, and the washes were performed in 4x SSC-0.1% Triton X-100 at 40°C (three washes, 3 min each). Hybridization analysis. Northern (RNA) and Southern analyses were performed according to standard protocols (1) . RNAs were isolated from cell lines by the method of Glisin et al. (23) or Chomczynski and Sacchi (9) . Radiolabelled probes were generated by the random-priming technique or PCR (21, 35) , using the primer pairs PJA-2 and PJA-3 (see above); PJA-8 (see above) and PJA-9 (bp 1890 to 1871; CTGACCTCGTGCAGATGGCA); PJA-11 (bp 646 to 627; TGAGCTTGGCAGCTCAGGTT) and PJA-12 (bp 248 to 267; GCAGGCTGAAGAAAGTCCCT); and PJA-14 (bp 2090 to 2109; GCCCACTCAGATGCTAGTGA) and PJA-17 (bp 2569 to 2588; CAAGGCCTTCAGTGTGTTCT).
Transfection and tumorigenicity assays. A 100-mm dish containing approximately 5 x 105 NIH 3T3 cells was fed with fresh medium 4 to 24 h prior to transfection. Five micrograms of plasmid DNA was precipitated with 3 M sodium acetate in the presence of 30 pug of high-molecularweight salmon sperm DNA in a 100-,u volume. The resulting precipitate was resuspended in 450 RI of H20 and incubated overnight at 37°C with gentle rocking. On the following day, 50 RI of 2.5 M CaCl2 was added dropwise while air was bubbled through a plugged pipette. This solution was then added dropwise to 500 pu1 of 2x HBS (280 mM NaCl, 50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid [HEPES], 1.5 mM Na2HPO4-12H20, pH 7.05) while air was bubbled through a plugged pipette. This solution was allowed to stand for 20 to 30 min at room temperature without agitation. The fine precipitate was then exposed to 3T3 cells for 8 h at 37°C. The medium was removed, and 2 ml of 15% (vol/vol) glycerol in phosphate-buffered saline (PBS) was added to cells for 90 s. Cells were washed with PBS and fed with fresh medium. After 24 to 48 h, cells were split 1:4 into 100-mm dishes containing G418 (600 ,ug/ml; total drug). Emergent colonies were then pooled to produce the nonclonal cell lines used in subsequent analysis (TF14A and TF14B transfected with the axl+ sense construct; TF15A and TF15B transfected with the axl+ antisense construct; TF16A and TF16B transfected with the pLXSN vector).
For analysis of transformation, half of the pooled G418-resistant cells were passaged once, grown to confluence, and scored for focus formation after 2 to 3 weeks. The remainder of these cells were expanded and injected into the flanks of athymic nude mice at concentrations of 1 x 105 and 5 x 105 cells per site. Tumor formation was scored 50 days after injection.
Baculovirus expression. The baculovirus transfer vector pBlueBac (Invitrogen, San Diego, Calif.) contains a ,-galactosidase expression cassette which permits recombinant plaque screening by addition of the chromagenic substrate X-Gal (5-bromo-4-chloro-3-indolyl-13-D-galactoside; 0.15 mg/ ml) to the agarose overlay. The cDNA insertion site of pBlueBac is an NheI site. An axl cDNA segment with full-length coding sequence and NheI-compatible ends was produced by cutting the axl cDNA clone 1-4 at the translation start site with NcoI. The resulting 3' overhangs were filled in with the Klenow fragment of DNA polymerase I plus dNTPs. After heat inactivation, the fragment was digested with EcoRI, ligated into Smal-EcoRI-digested pBluescriptll-KS plasmid, and then used to transform E. coli. The resulting plasmid contains an Spel site 12 Fig. 7B ) was performed according to published protocols (53) .
The polyclonal anti-axl antiserum was prepared by immunizing rabbits with gel-purified baculovirus-expressed axl protein. The antigen in the form of a Coomassie-stained gel slice was processed and administered in primary and (after 1 month) boost injections (28) . The anti-axl serum was collected 25 days following the boost injection. Immunoblot analysis was performed with the anti-axl antiserum and preimmune serum diluted 1:3,000 in TBST. Anti-rabbit immunoglobulin G-alkaline phosphatase conjugate was used as the secondary antibody. 
RESULTS
Cloning of the transforming axl gene. In our previous study, using a sensitive NIH 3T3 transfection-tumorigenicity assay, we identified a transforming gene in the DNA from the peripheral leukocytes of two CML patients that lacked ras mutations (47) . The resulting tumors arising from secondary transfection of tumor DNA gave rise to two explant tumor cell lines (AF6295 and AF3642) which harbored the same unique transforming human sequences. Several cosmid clones bearing human Alu repeats were isolated from a cosmid library derived from the DNA of one such explant tumor cell line, AF6295 (see Materials and Methods). Exon mapping identified a genomic fragment, pcc-1, that contained transcribed human sequences but was devoid of Alu repeats and mouse exons. Using pcc-1 as a probe on Northern blots, two axl mRNA species of 5.0 and 3.4 kb were identified in the explant 3T3 cell lines from the CML transfectants but not in untransformed NIH 3T3 cells or in 3T3 cells transformed by a mutant H-ras oncogene (Fig. 1) . Using pcc-1 as a probe, several axl-specific cDNA clones were isolated from cDNA libraries derived from AF6295 poly(A)+ RNA. All hybridized to the same 5.0-and 3.4-kb transcripts in the nude mouse tumor explant cell lines on Northern blot analysis. Sequence analysis of these cDNAs showed sequences in common with pcc-1. Since the original cDNA clones were short and did not contain poly(A)+ tails, a size-selected cDNA library was screened to identify fulllength cDNAs. Several clones were isolated and found to contain 3.2-kb inserts consistent in size with one of the two axl mRNA species. One of these clones, 1-4, was subcloned and sequenced.
Sequence analysis indicates that axl is a novel receptor tyrosine kinase. The sequence of clone 1-4 predicted a protein of 894 amino acids with two in-frame methionine residues that are candidate initiating amino acids based on Kozak consensus rules ( Fig. 2) (43) . Furthermore, an inframe termination codon lies 170 bp upstream from the first methionine codon. This methionine marks the beginning of a potential signal sequence of 32 amino acids (78) . A search of the EMBL, GenBank, and NBRF protein data bases indicated that the axl protein is a novel protein tyrosine kinase with significant homology to many known kinases, in particular eph, eck, elk, ros, trk, insulin receptor, insulin-related receptor, insulinlike growth factor 1 receptor, and sevenless (4, 19, 32, 44, 46, 49, 52, 69, 75) (Fig. 3B and C (27) . At approximately 100 amino acids carboxyl terminal to the Mg2+-ATP binding domain in axl lies the sequence DLAARN...(34 amino acids)...PVKWI AIE, which resembles but is distinct from a consensus sequence specific to tyrosine kinases, DLAARN...P(I/V)(K/ R)W(T/M)APE (27 To confirm axl's transforming potential, we constructed retroviral expression vectors containing the full-length axl cDNA (clone [1] [2] [3] [4] . In these constructs, transcription of axl is under the control of a Moloney murine sarcoma virus long terminal repeat, whereas the neomycin phosphotransferase gene, which confers resistance to the drug G418, is driven by a simian virus 40 promoter (55) . NIH 3T3 cells were trans- 1-4. and TF15B; cells transfected with the vector alone, TF16A and TF16B) and transformed foci cloned from cells transfected with the sense axl cDNA (subclones TF14B1, -14B2, -14B3, -14B7, and -14B10). Expression of the human ax! gene was seen in cells transfected by sense (TF14A and -B) and antisense (TF15A and -B) constructs, albeit at low levels. However, the axl-transformed subclones expressed high levels of axl RNA (Fig. 6A) . Thus, the second event in axl transformation appears to be a selection for cells expressing increased levels of axl message, indicating that overexpression of axl is necessary for 3T3 transformation.
We next tested the tumorigenic capacity of cells transfected with the genomic axl gene (AF6295) or axl cDNA (clones TF14B1, -14B2, -14B3, -14B7, and -14B10). Injection of either AF6295 or clone TF14B1, TF14B2, TF14B3, TF14B7, or TF14B10, all of which express high levels of axl message, resulted in the emergence of tumors within 9 days (Table 1) . There appeared to be a rough correlation between a short tumor latency with increased expression of axl RNA and protein, further supporting the notion that axl overexpression drives 3T3 transformation. In contrast, the initial axl transfectants (TF14A, TF14B, TF15A, and TF15B), vector-transfected NIH 3T3 cells, and untransformed NIH 3T3 cells did not form tumors within an incubation period of 50 days except for one of the clones transfected with vector alone (TF16A). This clone formed a tumor after 43 days and therefore represents background tumor formation.
Tyrosine kinase activity of axl. To test whether axl is a tyrosine kinase, we analyzed the phosphotyrosine profile of cells transformed by either genomic axl or an axl cDNA. Using an antiphosphotyrosine antibody, a novel 140-kDa tyrosine-phosphorylated protein was seen only in cells transfected with axl and not untransformed or ras-transformed NIH 3T3 cells (Fig. 6B) . Furthermore, the level of ppl40 correlated with the level of axl RNA in these cells (Fig. 6) .
To further test the tyrosine kinase activity of axl, recombinant axl protein was expressed in Sf9 insect cells, using the baculovirus expression system (Fig. 7) . In a Coomassiestained polyacrylamide gel of cellular proteins, a novel protein of approximately 104 kDa was induced in cells infected with a recombinant baculovirus containing axl cDNA (1-4) which was not present in wild-type-infected or uninfected cells (Fig. 7A) . The molecular size of this recombinant protein corresponds roughly to the predicted size (95 kDa) of the unglycosylated axl protein minus the signal peptide as deduced from the amino acid sequence by using the PEPTIDESORT program (Genetics Computer Group of the University of Wisconsin [14] ). Using an antiphosphotyrosine monoclonal antibody in Western immunoblot analysis, we detected a similar 104-kDa protein in axl-baculovirusinfected cells but not wild-type baculovirus-infected or uninfected cells (Fig. 7B) . In addition, we detected a 120-kDa protein which we suspect represents a partially glycosylated form of the ax! protein. As further evidence that the axl-baculovirus-induced bands represent actual tyrosinephosphorylated proteins, the immunoreactive bands were abolished by the inclusion of 1 mM phenylphosphate with the antiphosphotyrosine antibody (Fig. 7B, lane 9) . These data support the conclusion that the axl protein is a tyrosine kinase. Since insect cells do not glycosylate proteins to the same extent as do mammalian cells, we suspect that the 140-kDa phosphoprotein seen in axl-transformed 3T3 cells and the 120-kDa phosphoprotein in axl-infected Sf9 cells most likely represent fully processed and partially processed forms of axl, respectively. In support of this idea, we are able to detect 140-and 120-kDa proteins in the axl-transformed cell line AF6295 and 120-and 104-kDa proteins in axl-baculovirus-infected Sf9 cells, using a recently isolated polyclonal anti-ax! antibody in immunoblot analysis of cellular proteins (Fig. 7C) .
Cloning and characterization of c-axl. Many oncogenes have been shown to be activated by genomic alterations (24, 50, 59, 63, 73) . We investigated whether rearrangements or deletions of axl were present in the original patient DNAs from which axl was isolated as compared with DNAs from normal peripheral leukocytes and from the nude mouse tumor lines harboring the human axl oncogene. By using probes corresponding to the kinase, transmembrane, and extracellular domains of the cloned ax! cDNA in Southern blot analyses, no rearrangements of axl were detected in the DNAs from either the original CML patients or the nude mouse tumors as compared with DNAs from normal blood (data not shown). Furthermore, Northern blot analysis of axl transcripts from AF6295 and several normal and transformed cell types which also express axl mRNA (A549, A431, IMR-90, HeLa, and BG-9) revealed the identical 3.4-and 5.0-kb transcripts, making rearrangements and major deletions unlikely (Fig. 8A) .
To determine the mechanism by which axl was activated, we cloned cDNAs of the normal axl homolog (c-ax!). Using RNA from the normal human fibroblast IMR-90, we cloned a normal axl cDNA (clone 4-9) which appears identical to the transforming clone, 1-4. However, another cDNA clone isolated from the normal fibroblast library, 6-2, predicted an altered version of axl which lacked amino acids 429 to 437 (GQAQPVHQL) and contained a G-to-A transition at base 1170, resulting in the substitution of a leucine for a glutamic acid (Fig. 2) . We will refer to the predicted axl transcript from 1-4 as axl+ and that from 6-2 as axl-. Reverse PCR analysis of RNA with oligonucleotide primers flanking amino acids 429 to 437 showed both species of axl message present in the nude mouse tumor cell lines as well as other human cell lines and a primary human fibroblast, suggesting that axl+ and axl-are splice variants from the same gene. However, the axl+ species was overexpressed relative to the axl-species at an average ratio of 17:1 in the nude mouse tumor cells lines; in comparison, normal human fibroblasts exhibited a ratio of 2:1 (Fig. 9) . To test the transforming capacity of the axl cDNA, we expressed clone 6-2 in NIH 3T3 cells by using the pLXSN retroviral expression vector. 
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Using the same assay as with 1-4, expression of 6-2 also blast and breast epithelium. The near-ubiquitous expression resulted in the emergence of foci after a single passage of of axl suggests an important normal cellular function for this G418-resistant colonies (Fig. 5) (Fig. 10) . axl encodes a receptor tyrosine kinase with high amino acid similarity to the human trk, eph, eck, and ros proteins, insulin and insulin-related receptor, and insulinlike growth factor 1 receptor (Fig. 3 and 4) . Novel sequence differences in the kinase domain [i.e., KWIAIE compared with the consensus (K/T)W(T/M)APE] set the axl protein apart from known kinases. Supporting the conclusion that axl encodes a tyrosine kinase, we found a novel 140-kDa tyrosine-phosphorylated protein in axl-transformed NIH 3T3 cells. Increased expression of axl RNA in these cells correlated with increased levels of ppl40 and the tumorigenic potential of the transformed cells in nude mice. These results are consistent with the notion that ppl40 represents a phosphorylated axl protein. Expression of axl in baculovirus resulted in the production of two novel tyrosine-phosphorylated proteins of 104 and 120 kDa which most likely represent unglycosylated and partially glycosylated forms of axl. The difference in molecular size can be explained by the fact that insect glycoproteins are processed differently from mammalian glycoproteins. Both insect and mammalian cells add a characteristic high-mannose oligosaccharide as the first step in N-linked glycosylation (34, 36) . These glycoprotein intermediates are then processed to a trimannosyl core. Although mammalian cells further process this glycosylated intermediate by the addition of a variety of terminal sugar residues, no further processing takes place in insect cells (56) . There- (8) . Thus, the predicted axl peptide sequence suggests that axl may also complex with Ptdlns 3-kinase.
Although similar to other receptor tyrosine kinases, the axl protein represents a novel subclass of receptor kinases based on the unique structure of the extracellular region that juxtaposes IgL and FNIII repeats. Between amino acids 224 and 428 lie two FNIII repeats (Fig. 2) . This sequence motif was first identified as 60-to 100-amino-acid tandem repeats reiterated 15 times in fibronectin (71) . A number of extracellular matrix proteins and receptors contain FNIII repeats, including neural cell adhesion molecules, the growth hormone/prolactin receptor family, the product of the Drosophila sevenless gene, and several receptorlike tyrosine phosphatases (4, 22, 29, 58, 61) . In addition, we have found that a number of mammalian tyrosine kinases, including members of the insulin receptor family, also contain FNIII repeats. On the basis of homologies in the kinase domain and the presence of FNIII repeats, the axl protein appears most closely related to the insulin receptor family (Fig. 3) . However, two copies of IgL repeats encompassing amino acids (35) . Exposure time for lane 1 was 1 day; lanes 2 to 6 were exposed for 7 days. The position of the 28S RNA is indicated. Lanes: 1, AF6295; 2, A549; 3, A431; 4, IMR-90; 5, HeLa; 6, BG-9. (B) PCR analysis of RNA isolated from various cell lines. Differential PCR (57) was performed, using a-actin as a reference gene for semiquantitative analysis of axi expression. The ethidium bromide-stained polyacrylamide gel indicates the presence of a 303-bp axl fragment corresponding to the kinase domain and a 201-bp a-actin band as reference. Lanes: M, HaeIII-digested marker; 1, AF6295; 2, A549; 3, A431; 4, IMR-90; 5, HeLa; 6, BG-9; 7, K562; 8, LAM; 9, CML chronic-phase peripheral blood; 10, myelodysplastic syndrome peripheral blood; 11, normal peripheral blood 1; 12, no RNA. 37 through 212 are present amino terminal with respect to the FNIII repeats (Fig. 2) . Homologous IgL domains have also been found in many extracellular matrix proteins and receptors involved in protein-protein interactions, such as neural cell adhesion molecules, PDGFI3R, and the leukocyte common antigen-related protein (22, 29) . The combination of IgL and FNIII repeats is seen in the neural immunoglobulin superfamily of cell adhesion proteins and the protein tyrosine phosphatases. The axl protein, however, is the first receptor tyrosine kinase identified which incorporates both types of repeats. Though the functions of IgL and FNIII domains are unclear, their presence in numerous cell adhesion molecules and receptors suggests a potential function for these domains in cell-cell interaction.
Receptor tyrosine kinases have been classified into families based on sequence similarity and structural characteristics (27, 76) . The EGFR family contains two cysteine-rich repeats in the extracellular domain of a monomeric receptor.
The insulin receptor family has a disulfide-linked, a2P2
heteromeric structure and contains both a cysteine-rich domain and FNIII repeats in the extracellular region. with other known kinases reveals interesting structural similarities. As with the insulin receptor family, the eph, eck, and elk kinases contain a cysteine-rich region juxtaposed to FNIII repeats (Fig. 4) . However, in contrast to the insulin receptor family, the eph, eck, and elk kinases are characterized by a vestigial IgL repeat near their amino termini and do not contain proteolytic processing sites for the formation of a and P subunits ( Fig. 3 and 4) . Thus the eph family of kinases represents a related but distinct subclass within the insulin receptor family. By amino acid homology, the axl protein is most similar to the insulin receptor family. However, the extracellular domain of the axl protein lacks a cysteine-rich region and possesses the unique juxtaposition of two IgL and two FNIII repeats, indicating that this protein is a separate subclass within the insulin receptor kinase family. Although not previously described, we have observed that the extracellular domain of the trk protein also contains IgL and FNIII repeats, making it similar in structure to the axl protein. Interestingly, the FNIII repeats in the trk protein closely resemble IgL repeats (Fig. 3) . Bazan has observed that IgL and FNIII domains are similar in overall structure, suggesting that these domains evolved from a common ancestral gene (5) . It is possible, therefore, that the trk protein represents an ancestral kinase with domains intermediate between IgL and FNIII repeats. In view of these sequence associations, we propose that the eph, eck, and elk proteins represent one subclass and the axl and trk proteins represent another subclass of receptor tyrosine kinases that are evolutionarily related to the insulin receptor family (Fig. 4) .
In contrast to other oncogenic receptor kinase genes such as ret, trk, and fms (CSF-1R), the normal c-axl gene was activated by overexpression rather than by genomic alterations such as mutation or rearrangement. Overexpression of normal receptors (e.g., erbB2) can also result in neoplastic transformation in an apparently ligand-independent fashion (16) seen in the generation of the insulin receptor in which a 36-nucleotide exon (exon 11) coding for a portion of the extracellular domain is spliced into the transcript in some tissues and not in others (67) . Though the function of this differential splicing event in both the insulin receptor and the axl protein remains unclear, our data indicate that both forms of the axl protein are biologically indistinguishable in terms of their transforming capacity in NIH 3T3 cells. This also suggests that the substitution of leucine for glutamic acid at amino acid 338 represents a sequence polymorphism as opposed to an activating mutation. This view is further supported by the finding that another cDNA clone (clone [4] [5] [6] [7] [8] [9] from the normal human fibroblast cDNA library has the same sequence as clone [1] [2] [3] [4] with regard to amino acid 338 and the presence of the 27-base insert. These observations are consistent with the conclusion that axl transformation is due to overexpression of a normal receptor tyrosine kinase. Similar to axl, the eph gene has been shown to have weak transforming properties when overexpressed in 3T3 cells (51) .
Several lines of evidence underscore the potential role of axl in normal cellular function. First, the transforming activity of axl suggests a role for the proto-oncogene in proliferation. Second, axl expression can be detected in the majority of cell types examined, implying a significant role for axl in normal cellular activity. This notion is further supported by the near-ubiquitous expression of axl message in various mouse organs (58a) . Third, axl expression is altered in hematopoietic differentiation. axl RNA levels are augmented >10-fold in the CML cell line K562 upon addition of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate), which induces megakaryoblastic differentiation in these cells (57a, 74) . Using a PCR-based cloning strategy, Partanen et al. (60) have detected novel tyrosine kinases expressed in differentiated K562 cells. One of these partial cDNA clones, designated JTK 11, has the same sequence as the axl protein at amino acids 669 through 736 in the kinase domain (60) .
The specific role of axl in the pathogenesis of CML remains unclear. However, our data suggest that axl is a CML-associated oncogene. First, identical forms of axl emerged as the transforming gene in two of eight non-mutant ras-bearing CML cases analyzed in a transfection-tumorigenicity assay (47) . We have applied this assay on >40 DNAs from numerous malignancies (breast carcinomas, squamous cell carcinomas of the skin, renal cell carcinomas, and other types of leukemias) and have not uncovered axl in any transformant (46a). Thus, an oncogenic axi gene has been found only in CML samples. Since axl-induced transformation of 3T3 cells results from overexpression of the transfected proto-oncogene, these two CML samples may contain mutations in the axi promoter or as yet uncloned 5' untranslated sequences which may result in overexpression of the axl kinase. Activation of the Ick proto-oncogene occurs through a similar mechanism in which mutations in the 5' untranslated region increase the translational efficiency of the gene, resulting in overexpression of the oncoprotein (48) . Characterization of the axl promoter region will address this possibility. In addition, using chromosomal in situ hybridization (45), we have localized axl to chromosome 19, band q13.2 ( Fig. 10) , where another oncogene, bcI3, is also found (19q13.1-13.2) (42, 54) . Interestingly, chromosome 19 abnormalities (especially trisomy 19) are frequently associated with the conversion of chronic-phase CML to blast phase occurring in approximately 18% of blast crisis samples (64) . Future studies will help define axl's role in human malignancies.
